These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21755648)

  • 21. Narrative review of methods and findings of recent studies on the carriage of meningococci and other Neisseria species in the African Meningitis Belt.
    Greenwood BM; Aseffa A; Caugant DA; Diallo K; Kristiansen PA; Maiden MCJ; Stuart JM; Trotter CL
    Trop Med Int Health; 2019 Feb; 24(2):143-154. PubMed ID: 30461138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.
    Mohammed I; Iliyasu G; Habib AG
    Pathog Glob Health; 2017 Feb; 111(1):1-6. PubMed ID: 28081671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Meningococcal meningitis epidemics in sub-Saharan Africa and the meningococcal A conjugate vaccine].
    Nicolas P
    Med Sante Trop; 2012; 22(3):246-58. PubMed ID: 23186941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.
    Marc LaForce F; Ravenscroft N; Djingarey M; Viviani S
    Vaccine; 2009 Jun; 27 Suppl 2():B13-9. PubMed ID: 19477559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.
    Okoko BJ; Idoko OT; Adegbola RA
    Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
    Xie O; Pollard AJ; Mueller JE; Norheim G
    Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
    MenAfriCar consortium
    J Infect Dis; 2015 Oct; 212(8):1298-307. PubMed ID: 25858956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of meningococcal meningitis outbreaks in sub-Saharan Africa.
    Chippaux JP
    J Infect Dev Ctries; 2008 Oct; 2(5):335-45. PubMed ID: 19745499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt.
    Carod Artal FJ
    Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningitis epidemics shift in sub-Saharan belt.
    Zhao S; Lin Q; He D; Stone L
    Int J Infect Dis; 2018 Mar; 68():79-82. PubMed ID: 29408359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outbreak news. Meningococcal disease in the African meningitis belt.
    Wkly Epidemiol Rec; 2008 Mar; 83(10):90-1. PubMed ID: 18326110
    [No Abstract]   [Full Text] [Related]  

  • 33. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons from the Meningitis Vaccine Project.
    LaForce FM; Djingarey M; Viviani S; Preziosi MP
    Viral Immunol; 2018 Mar; 31(2):109-113. PubMed ID: 29116892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal meningitis.
    Aguado T; Bertherat E; Djingarey M; Kandolo D; Kieny MP; Kondé K; LaForce FM; Nelson CB; Perea W; Préziosi MP
    Nat Rev Microbiol; 2005 Jan; 3(1):10-1. PubMed ID: 15635779
    [No Abstract]   [Full Text] [Related]  

  • 37. Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.
    Mustapha MM; Harrison LH
    Hum Vaccin Immunother; 2018 May; 14(5):1107-1115. PubMed ID: 29211624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine.
    LaForce FM; Okwo-Bele JM
    Health Aff (Millwood); 2011 Jun; 30(6):1049-57. PubMed ID: 21653956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningitis epidemics in Africa: a brief overview.
    Teyssou R; Muros-Le Rouzic E
    Vaccine; 2007 Sep; 25 Suppl 1():A3-7. PubMed ID: 17643560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
    Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.